Form 4: Exelixis Director Maria Freire Receives RSU Grant

Director Maria C. Freire was granted 8,367 restricted stock units as part of the Exelixis, Inc. 2017 Equity Incentive Plan.

Summary

• Director Maria C. Freire acquired 8,367 restricted stock units (RSUs) on May 27, 2026.
• The grant was issued under the Exelixis, Inc. 2017 Equity Incentive Plan.
• Each RSU represents the economic equivalent of one share of common stock.
• The total beneficial ownership for the director following this transaction is 109,186 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Vesting is subject to the Reporting Person's continuous service through the May 27, 2027, vesting date.

Future Outlook

The RSUs are scheduled to vest 100% on May 27, 2027, provided the director maintains continuous service with the company.

Industry Context

StockSavvy.ai notes that equity grants to board members are a standard corporate governance practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The use of RSU grants for non-employee directors is consistent with compensation structures at peer mid-cap biotechnology firms.
• Vesting schedules of one year for director equity are common practice to ensure retention and commitment.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 8,367 RSUs on May 27, 2027.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation